Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-04-30

Investigation of putative signaltransduction processes of normal pr ion protein and their role in spongiform encephalopathy pathogenesis

Objectif



There is a public health concern that the incidence of Creutzfeldt-Jakob disease (CJD) may increase over the next one or two decades because the new variant of Creutzfeldt-Jakob disease (nvCJD) is believed to have arisen from infection via meat products contaminated by the bovine spongiform encephalopathy (BSE) agent. Since there is no treatment for CJD, it is prudent to learn more about the pathogenesis of CJD and the other transmissible encephalopathies (TSEs) since greater knowledge will increase the chances of a successful treatment being devised; greater knowledge may also aid elimination of the animal TSEs.

Understanding pathogenic mechanisms usually requires knowledge of the normal corresponding physiological processes. The objectives of this proposal are to increase knowledge of the normal and pathogenic properties of the putative infectious agent, the prion protein.

We aim to focus on investigating our hypothesis that the prion protein is involved in signal transduction. We and others have demonstrated that prion protein appears to be involved in cell signalling and that this involves changes in intracellular calcium concentrations, but the particular signal transduction pathways have yet to be identified. There is also evidence that in the TSEs, disruption of normal prion protein function occurs and that this may be the mechanism underlying pathogenesis; disruption of normal prion protein function may be the mechanism whereby prion amyloid deposits exert their neurotoxic effects, since there is an absolute requirement for expression of normal prion protein for the pathogenic forms of the prion protein to exert their neurotoxicity.

Understanding prion protein function will therefore most probably help us to understand the neurodegenerative mechanisms in the TSEs and lead to the identification of therapeutic targets for CJD. The proposed consortium will bring together complementary scientific expertise in TSE pathogenesis and pathology, transgenic animals, gene delivery to neurons, cell and molecular biology, intracellular calcium imaging, signal transduction, pathogenic mechanisms associated with amyloid in Alzheimer's disease, and state of the art protein chemistry and protein sequencing; the consortium will also recruit to TSE research new scientists without prior experience of the TSE field and so expand and enhance the EU effort into treating and eliminating these important diseases.
Our specific objectives are:

- to generate stably transfected mouse neuroblastoma cell lines expressing mutant mouse prion proteins corresponding
- to known human prion mutations; - to generate similar cellular models of mutant prion protein expression, using adenoviral vectors, in primary cultures of hippocampal neurons from prion-null transgenic mice;
- to determine if the mutant prion proteins in the cell lines and in primary neuronal cultures are protease-resistant;
- to perturb prion protein expressed in the cell lines and in primary neuronal, astrocytic and microglial cell cultures by antibody to prion protein, by recombinant prion protein and by synthetic peptides corresponding to different domains of the prion protein, including a neurotoxic peptide, and
to investigate signal transduction changes by:
investigating the mechanism by which prion protein regulates intracellular calcium concentrations;
and using combined 2-D gel electrophoresis and nano-electrospray mass spectrometry to identify post-translationally modified target proteins by mass spectrometric peptide sequencing.

The successful outcome of the project will be increased understanding of pathogenic mechanisms in the TSEs and the potential identification of novel therapeutic targets to treat the human TSEs.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

Données non disponibles

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

CSC - Cost-sharing contracts

Coordinateur

Institute of Psychiatry
Contribution de l’UE
Aucune donnée
Adresse
De Crespigny Park Camberwell
SE5 8AF London
Royaume-Uni

Voir sur la carte

Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.

Aucune donnée

Participants (3)

Mon livret 0 0